Obesity Management

A conversation with Becky Davis, principal at Charles River Associates, at Asembia’s AXS25 Summit.

Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.

In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.

One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.

Investigators find 5 distinct obesity trajectories that influenced brain morphology, function, and cognition.

With expertise in the management and treatment of diabetes, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, shared her insights on counseling patients using GLP-1 medications.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.

Lydia Newsom, PharmD, discusses injection techniques, managing side effects, and the importance of collaboration between the healthcare team.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joined Drug Topics to discuss which indications patients typically gravitate toward for the use of GLP-1 medications.

Lydia Newsom, PharmD, discusses how to support patients who are struggling with injection techniques or gastrointestinal side effects of GLP-1s.

Lydia Newsom, PharmD, discuses how pharmacists can support patients using GLP-1s.

Researchers explored how social media advertising of lifestyle drugs contributes to the normalization of use for semaglutide, testosterone, and sildenafil.

A conversation with Lydia Newsom, PharmD, clinical associate professor of pharmacy practice at Mercer University College of Pharmacy.

On both an individual and societal level, researchers explored how social, cultural, and ethnic determinants impact the treatment and management of obesity.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed the common trends in GLP-1 use she’s seen amongst her patients as well as her extensive experience working with this medication class.

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed her experience when beginning to counsel patients using GLP-1 medications.

Researchers analyzed the association between adherence to a Mediterranean diet and obesity cancers, with a focus on the mediating role adiposity plays throughout the process.